Table 3.

Danoprevir potency against treatment-emergent NS3 substitutions

NS3 protease varianta	EC50, nM (mean ± SD)b	Fold changec
R155K	45.1 ± 30.8d	410
R155Q	6.3 ± 2.6e	57
D168E	3.2 ± 2.8d	29
D168V	10.4 ± 6.3d	93
D168T	33.0 ± 16.4d	300
I71V	0.06 ± 0.01d	0.57
V170I	0.12 ± 0.06d	1.05
Wild type	0.11 ± 0.05	N/A

^aIntroduced as site-directed mutations (SDMs) into con1b HCV replicon genetic background if Con-1 sequence differed from identified substitution.

^bData are from at least three independent experiments.

^cFold change relative to parental Con-1 HCV replicon. N/A, not applicable.

^dRelative replication capacity of variant replicon is greater than 50% of wild type.

^eRelative replication capacity of R155Q variant is approximately 20% of wild type.